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ABSTRACT: BACKGROUND: Surveillance
programmes for women at increased genetic risk of
breast cancer are being established worldwide but
little is known of their efficacy in early detection of
cancers and hence reduction in mortality.
METHODS: Data were contributed from seven
centres participating in the EU Demonstration
Programme on Clinical Services for Familial Breast
Cancer.  All breast tumours (n = 161) detected
prospectively, from the time of enrolment of women
in a screening programme, were recorded.  Analysis
took account of age at diagnosis, whether tumours
were screen-detected or not, their pathological stage
and outcome by Kaplan—Meier survival plots.
RESULTS: Mean age at diagnosis was 48.6 years.
Overall, 75% of tumours were detected in the course
of planned examinations.  For women under age 50 at
diagnosis, this figure was 68%.  Eighteen percent were
mammographically negative, (23% in patients under
age 50).  At first (“prevalence”) round and at follow-
up screening, 16% and 22% of tumours respectively
were carcinoma in situ (CIS) while 27% and 22%
respectively had evidence of nodal or distant spread
(CaN+).  Comparison of screen-detected and other
tumours showed that the latter were more frequently
mammogram-negative and CaN+.  Overall five-year
survival was 89% and five-year event-free survival
86%.  Five-year event-free survival was 100% for
CIS, 88% for invasive cancer without nodal or distant
spread and 67% for CaN+.
CONCLUSIONS: The majority of cancers arising in
women at increased genetic risk of breast cancer can
be detected by planned screening, even in those under
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age 50.  Surveillance should include regular expert
clinical examination and teaching of “breast
awareness” as well as mammography.  Attention to
the logistics of screening programmes may improve
still further the proportion of tumours that are screen-
detected.  The trend towards earlier pathological stage
in tumours detected during follow-up rounds and the
preliminary findings on survival analysis suggest that
this approach will prove to be of long-term benefit for
breast cancer families.
KEYWORDS: Inherited, familial, breast cancer,
prognosis, stage, diagnosis, survival, screening,
mammography
INTRODUCTION
Familial breast cancer has been recognised at
least since 1866 as a dominantly inherited trait
characterised by early onset of disease and high
mortality [1].  In many centres, systematic risk
assessment and screening are now offered to
female members of breast cancer families but
there is little evidence from which to judge the
effectiveness of these programmes.  The few
published reports have recorded small numbers
of tumours prospectively diagnosed,
documenting clinical and pathological stage but
with no information on survival [2–5].
The demonstration that germline mutations in
BRCA1 or BRCA2 underlie a substantial
proportion of inherited breast cancers has made
possible predictive testing to identify women at
particularly high risk.  This has stimulated debate
on the relative merits of systematic screening
versus prophylactic mastectomy as protective
strategies [6].
The European Union has funded a multi-centre
collaborative Demonstration Programme to
evaluate clinical services for familial breast
cancer.  In all centres women are defined as
eligible to receive these services if their genetic
risk is at least twice that of the general
population, based on the Claus model [7] (i.e. at
least one first degree relative with breast cancer
diagnosed before age 40 or one first degree and
one second degree relative with breast cancer,
mean age of diagnosis > 55years, or more than
two close relatives affected — one first degree).
We have described the surveillance programmes
offered in the different centres [3,4,8].  Here we
report the findings with respect to breast cancers
diagnosed within these programmes, their means
of detection, pathological stages and preliminary
data on survival.
MATERIALS AND METHODS
Women were included in the present study if
they were at sufficiently high genetic risk, as
defined above, and, at enrolment, had no signs or
symptoms suggestive of breast cancer (previous
or concurrent).  Numbers contributed from each
centre are specified in Table 1.  The period of
study for each centre was from the time of
establishment of a surveillance programme until
the end of the latest month for which complete
data are available.  The date of enrolment for
each woman was the date on which she was
accepted for inclusion in a surveillance
programme.  In some centres, for logistic
reasons, there could be a delay of several months
between registration and first clinical/mammo-
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graphic examination.
Until very recently, entry to surveillance
programmes in all the participating centres has
been based on family history alone, since the
availability of molecular diagnosis has been
limited and DNA analysis has been applied
mainly to families already enrolled in the
programmes.  The number of women with known
BRCA1 or 2 mutations is still too small to be
used as a grouping variable.  They are therefore
not treated separately in the analyses.  All
screening protocols include mammography
(usually annually) from age 35 to 50 years,
starting at a younger age if there has been very
early onset disease in the family.  This has been
combined with regular expert clinical
examination and instruction on self-examination
of the breasts (“breast awareness”).  For women
over age 50, screening intervals in some centres
have been longer (18 months or two years).
All centres have interpreted indications for
cytology (fine needle aspiration and core biopsy)
in this high-risk population liberally, placing the
need for enhanced sensitivity ahead of concern
for specificity.  The frequency of invasive
investigations has been evaluated for three of the
participating centres.  Rates were similar (3.9–
7.3% of all examinations) and the extra demands
on pathology services have been minimal [9].
Two of the participating centres have
previously reported on prospectively detected
cancers [3,4].  These series (updated) are
included in the present report.  Cancers were
classified as carcinoma in situ (CIS), invasive
carcinoma without evidence of spread (CaN0) or
invasive carcinoma with nodal or distant spread
(CaN+), based on pathological findings after
excision.  Follow-up period was recorded as the
time between definitive diagnosis and latest
clinical examination.  Tumours were designated
“screen-detected” cancers if they were found on
mammography, clinical examination, or both,
within a planned surveillance programme.  Those
presenting outside a planned surveillance
examination were either “interval” tumours (i.e.
where there had been a previous negative
screening examination) or “others” (to include
those presenting clinically before a planned first
screening examination was actually undertaken).
The existence of this last group emphasises that
evaluation of surveillance protocols for those at
high risk must be based on “intention to screen”
since delays in implementation of that intention,
as well as unintended prolongation of screening
intervals, may have adverse effects on
programme performance.
Tumours were considered mammogram-
negative if interpretation of the mammogram did
not lead to additional investigations and/or if the
radiologist could not confirm any suspicion of
cancer raised by the clinical examination.  Ten
tumours (seven of which were non-screen-
detected cancers) were excised without prior
mammography.  In calculating the proportion of
mammogram-negative tumours, the denominator
includes those not examined mammographically,
unless otherwise stated.  Contra-lateral breast
cancer was treated as a separate tumour in
recording stage at diagnosis, so nine patients
were counted twice.  However each patient was
counted once only (using first tumour) for
survival analysis, using Kaplan—Meier plots in
the SPSS statistical PC programme.  For overall
survival, death was the event scored.  For event-
free survival, tumour spread (loco-regional, nodal
or distant) or cancer-related death were recorded
as events.  For patients with metastatic disease at
diagnosis, only death was scored as an event.  No
breast cancer patient in this series experienced
any event (spread or death) which was not related
to the first breast cancer recorded.
Age-specific mean sojourn time (MST or “lead
time”), i.e. the time that a breast cancer may be
detectable on examination before presenting
clinically, was derived as follows.  The average
MST for breast cancer in this age group, (1.25
years) from published Swedish population studies
[10,11], was applied to estimate the observation
period covered by the first examination (the
“prevalence round”) and hence to deduce the
annual incidence rate for our total high-risk
population.  The validity of this calculated rate
was then tested by comparing it with the
observed incidence rate on follow-up.
Predicted numbers of cancers were derived
from local age-specific incidence rates. Statistical
P. Møller et al. / Early Diagnosis and Treatment in Women with a Family History of Breast Cancer182
associations were tested by Fisher’s exact p (one
sided).
RESULTS
One hundred and sixty-one breast cancers in
152 women were observed prospectively in
women enrolled in formal surveillance
programmes because of perceived genetic risk.
This is by far the largest series reported from any
such study.  Mean age at diagnosis was 48.6
years, range 28 to 71 years, with 91 (57%) being
under age 50, including 31 (19%) under age 40.
Table 2 records the characteristics of all the
tumours observed, categorised by pathological
stage, mammographic findings and whether they
were screen-detected or not.  Table 3 gives
figures for women diagnosed before age 50
separately, but no statistically significant
differences were seen between outcome in
patients under and over 50 years of age.
We have previously published that annual
incidence rate in the Norwegian series was
0.0064 calculated, as indicated above, from
findings in the first round, and 0.0086 observed
at follow-up [3].  Data from the Manchester
series [4] allowed similar calculations, resulting
in annual incidence rate 0.0025 derived from first
round, and 0.0024 observed at follow-up.  The
closeness of agreement between calculated and
observed data indicates that the assumed Mean
Sojourn Time (MST) of 1.25 years is accurate.
Forty tumours (24.8%) presented clinically and
were detected by the patients themselves.  Two
tumours were found on planned examinations
outside the specific programme and, for the
purposes of analysis, were classified as screen-
detected.  Among the 40 self-detected tumours, 2
(5%) were CIS, 22 (55%) were CaN0 and 16
(40%) were CaN+.  Compared with screen-
detected tumours, interval and “other” cancers
were less often CIS (p = 0.01) and more
frequently CaN+ (p = 0.006).  Thirteen out of
33 (39%) non-screen-detected cancers were
mammographically negative (when examined on
clinical presentation), versus 15 of 118 (13%)
screen-detected (p = 0.001).  Overall, 6 of 32
(19%) CIS, 16 of 87 (18%) CaN0 and 6 of 32
(19%) CaN+ cancers were mammographically
negative.
The proportion of CIS tumours was higher on
Table 2
Results stratified on CIS, CaN0 and CaN+ for first round and for follow-up separately. Mammographic negative
tumours (miming) and interval cancers (interval) in each row are specified. Percentages in parentheses were
calculated as number in cell divided by sum for row
CIS CaN0 CaN+ Sum Mamneg Not screen-detected
First round 8 29 14  (27%) 51 8  (16%) 11  (22%)1
Of these - mamneg 2 4 2  (38%) 8 5  (63%)1
- not screen-detected 0 6 5  (45%) 11 5  (45%)
Follow-up 24 62 24  (22%) 110 20  (18%) 29  (26%)
Of these - mamneg 4 12 4  (20%) 20 8  (40%)
- interval 2 16 11  (38%) 29 8  (28%)
1 After filed “intention to screen” at genetic counselling, before first examination — time delay up to one year in some parts of
the series.
Table 3
Results from follow-up (after first round) for patients aged less than 50 years considered separately
CIS CaN0 CaN+ Sum Mamneg Not screen-detected
Follow-up 15 32 15  (24%) 62 14  (23%) 20  (32%)
Of these - mamneg 1 9 4  (29%) 14 5  (36%)
- interval 1 11 8  (40%) 20 5  (25%)
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follow-up than in the first screening round (22%
vs. 16%); conversely, the proportion of CaN+
tumours was lower on follow-up (22% vs. 28%)
but these differences did not reach statistical
significance.
All deaths in the observation period were
breast cancer related.  Five year overall survival
was 0.89 (SE 0.05).  Five year event-free survival
for the whole group of women with tumours was
0.86 (SE 0.06).  Five year event-free survival for
patients with CIS was 1; for those with CaN0 it
was 0.88 (SE 0.06) and for those with CaN+,
0.67 (SE 0.20) (Figure 1).
DISCUSSION
Women aware of their increased genetic risk
of breast cancer have to make a difficult choice
between enrolment in a surveillance programme,
participation in a chemoprevention trial or
prophylactic mastectomy.  In the families
described, few have actively pursued the last
option but a recently published retrospective
review [6], showing that surgery can reduce
cancer incidence by 90%, has generated
considerable interest and adds urgency to the
question of how effective the alternatives may be,
particularly in view of lack of empirical results
for efficacy of mammographic and clinical
follow-up examinations in premenopausal
women at risk.
This study demonstrates conclusively that
surveillance programmes for women whose
family histories suggest they may be at increased
risk can detect the majority of breast tumours,
including those arising at an early age.  Over
75% of tumours were detected in the course of
planned screening examinations.  Attention to the
logistics of service provision might improve this
figure still further: Eleven of the forty non-
screen-detected cancers presented sympto-
matically in the period between registration of the
patient for surveillance and institution of clinical/
mammographic screening.  In addition, seven of
11 (64%) interval cancers with spread at follow-
up were detected more than 6 months after the
previous examination (data not shown),
indicating the possibility of reducing the numbers
of pathologically advanced tumours by reducing
the interval between screening examinations.
Sixty percent of non-screen-detected cancers
were still node-negative at diagnosis.  This may
be interpreted as a success for the policy of
Fig 1.  Event-free survival according to stage at diagnosis. CIS n = 32, CaN0 n = 91, CaN+ n = 38.
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encouraging regular self-examination or “breast
awareness”.  Nevertheless it is lower than the
corresponding proportion of screen-detected
tumours (82%) and is comparable to the figure
for tumours in unscreened women under age 50
from the Swedish two counties trial [12].
Overall, twenty-eight tumours (18%) were
negative on mammography despite the fact that
the attention of the radiologist could be drawn to
suspicious areas detected on clinical examination.
This figure was higher (23%) for the tumours
diagnosed under age fifty, though the difference
is not statistically significant.  These findings
emphasise the need to include regular expert
clinical examination as a component of screening
for this high-risk group.
Rates of CIS were higher than expected in both
the first and subsequent screening rounds
(Table 2).  The high frequency of CIS at follow-
up was first noted in the Norwegian data [3] and
is confirmed in the additional series reported
here.  If CIS was not associated with genetically-
caused infiltrating cancers, the ratio of CIS to
infiltrating cancers should have been relatively
low in our cohort, enriched for women at
increased genetic risk.  The findings suggest that
CIS is indeed associated with familial breast
cancer and that, in the high-risk population, new
CIS lesions are continuing to arise at an
appreciable rate.  In this setting, CIS is
presumably a precursor of invasive cancer, in
which case, one feature of an effective screening
programme should be the trend observed here,
namely an increasing proportion of tumours
detected at the stage of CIS and a decrease in
those with nodal or distant spread.  This concept
has parallels with inherited colon cancer where
invasive cancer arises within the dysplastic
adenomatous polyp and removal of the polyp
protects against cancer [13].  It is also in keeping
with a previous report that abnormal proliferation
of the breast epithelium segregates as a dominant
trait in breast cancer kindreds [14].
In this series, stage-specific 5-year survival
was similar to that reported for sporadic breast
cancer [15], while the overall 5-year survival was
better.  This again indicates that prognosis is
related to stage at diagnosis, and that the effect of
our intervention was mediated through diagnosis
at an early stage.
The actual tumour incidence rates were much
higher than age-specific rates for the general
population but differed considerably between two
centres (eight times higher in Norway, two and a
half times higher in Manchester), which probably
reflects differences in the risk profiles of the two
clinic populations, given that a substantial
proportion of Norwegian breast cancer families
have subsequently been shown to carry founder
mutations in BRCA1 [16], while there have been
no comparable findings in Manchester.  The only
inference drawn from this part of the study was
that familial breast cancer has the same age-
related MST as sporadic cancer.  Applying 1.25
year lead time [10,11] and comparing the
outcome in this series with historical reports for
BRCA1 mutation carriers [17,18], follow-up
results to date are encouraging although several
more years of observation will be required before
the benefits of planned surveillance in this
genetically high-risk group can be fully
evaluated.
Inherited breast cancer is clearly not
homogenous with respect to phenotypic
appearance and prognosis.  For example, there is
evidence that tumours arising on a background of
BRCA1 mutations are characterised by
histopathological signs associated with poor
prognosis, including low frequency of CIS [19].
If so, BRCA1 mutation carriers may need more
frequent follow-up examinations because of a
shorter “time-window” for diagnosis before
spread.  Our continued monitoring of the patients
described, and determination of their carrier
status for relevant mutations, may clarify this.
The same problems of possible different effects
of intervention for distinct genetic subgroups,
also apply to any alternative strategy to prevent
or cure inherited breast cancer.
While there remains a great need to match
management strategies to more precise
definitions of risk, women with family histories
of breast cancer can now choose, on the basis of
real data, between prophylactic surgery [6] and
regular surveillance.  It is interesting to compare
these data with the predictions upon which a
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published decision analysis [20] was based.  The
presumption that prophylactic mastectomy would
confer 85% protection now appears slightly
conservative, while the estimate that a screening
programme would detect 80% of tumours at the
node-negative stage (and 20% after metastatic
spread) has yet to be confirmed, though these
figures seem attainable.  The conclusions that,
“on average, 30 year old women who carry
BRCA1 or BRCA2 mutations gain from 2.9 to
5.3 years of life expectancy from prophylactic
mastectomy” and that “gains in life expectancy
decline with age at the time of prophylactic
surgery”, are likely to prove accurate.
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